Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4).
A global multicenter, randomized, double-blind, placebo-controlled, pivotal phase III study. To evaluate overall survival (OS) of Lisaftoclax (APG-2575) combined with azacitidine (AZA) vs. placebo combined with azacitidine in newly diagnosed patients with HR-MDS.
Higher-risk Myelodysplastic Syndrome
DRUG: Lisaftoclax (APG-2575)|DRUG: Azacitidine Injection|OTHER: Placebo
Overall Survival（OS）, The primary endpoint was overall survival (OS), defined as the time from the date of randomization to the date of death of any cause., Up to 5 years
Safety evaluation based on the adverse event concurrence, Number of treatment emergent adverse events (TEAEs) and treatment related adverse events (TRAEs) will be evaluated., Up to 5 years
This study intends to enroll patients with HR-MDS to receive the therapy of Lisaftoclax (APG-2575) combined with azacitidine (AZA) or placebo combined with azacitidine.